Nephros (NASDAQ:NEPH) Upgraded at Wall Street Zen

Nephros (NASDAQ:NEPH) was upgraded by equities researchers at Wall Street Zen to a “strong-buy” rating in a research report issued on Saturday.

NEPH has been the subject of several other reports. Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a research note on Wednesday, October 8th. Maxim Group upped their target price on Nephros from $4.50 to $6.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Nephros Stock Down 8.3%

Shares of NASDAQ NEPH opened at $4.89 on Friday. Nephros has a 12 month low of $1.36 and a 12 month high of $5.98. The company has a market cap of $51.83 million, a price-to-earnings ratio of 40.75 and a beta of 1.32. The business has a fifty day simple moving average of $4.44 and a 200-day simple moving average of $3.46.

Nephros (NASDAQ:NEPH) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.04. The firm had revenue of $4.40 million during the quarter, compared to the consensus estimate of $3.60 million. Nephros had a return on equity of 14.89% and a net margin of 7.95%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nephros stock. Geode Capital Management LLC raised its holdings in Nephros Inc. (NASDAQ:NEPH) by 3.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 93,187 shares of the company’s stock after buying an additional 2,898 shares during the quarter. Geode Capital Management LLC owned 0.88% of Nephros worth $381,000 at the end of the most recent quarter. 41.10% of the stock is currently owned by institutional investors and hedge funds.

Nephros Company Profile

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.